Moetaz B Albizem

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.

K. Mahaffey, D. Wheeler, G. London, 2007, Clinical journal of the American Society of Nephrology : CJASN.

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

R. Giugliano, M. Sabatine, M. Eriksson, 2014, Journal of the American College of Cardiology.

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.

F. Locatelli, M. Chonchol, H. Abboud, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.

S. Rosansky, S. Moe, J. Cunningham, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial

Heather B. Gonzalez, John D. Davis, Travis J. Bernardo, 2022, The Lancet Infectious Diseases.

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.

B. Culleton, J. Coburn, S. Roger, 2005, Journal of the American Society of Nephrology : JASN.

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

P. Ponikowski, S. Solomon, M. Pfeffer, 2013, European journal of heart failure.

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

R. Giugliano, M. Sabatine, R. Weiss, 2014, European heart journal.

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

R. Giugliano, M. Sabatine, R. Weiss, 2014, European heart journal.